Chordate makes progress in Italy, China and Saudi Arabia

In Italy, 11 clinics are using the K.O.S treatment and the aim is to reach more by 2023. In China, the joint venture company Changyong Medical Technology has submitted a product registration application for the rhinitis treatment. In addition, Chordate Medical is resuming customer deliveries in Saudi Arabia. Biostock news service interviews CEO Anders Weilandt about the goals of 2023.

CEO Anders Weilandt on the introduction of K.O.S in Italy:

“The positive results from the migraine study have given further momentum to this project. Italy is an important market for us, partly because it’s one of Europe’s largest medtech markets and partly because we expect that K.O.S will soon be offered both for chronic rhinitis and chronic migraine in the country. That makes Italy a strong example of proof-of-concept for us.”

Read the interview here.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy